Matthew Lunning, DO, FACP

Dr. Lunning acknowledges country-specific cost-access realities for novel therapies, noting he prescribes what the evidence supports and then navigates insurance processes including peer-to-peer reviews when needed.

Dr. Graff addresses the persistent gap between the CAR-T evidence base and real-world utilization.

Dr. Johnson discusses the FDA's April 2026 update to the epcoritamab label permitting outpatient monitoring for the first full 48 mg dose in relapsed/refractory DLBCL.

Dr. Graff reviews the EPCORE DLBCL-1 Phase 3 trial comparing epcoritamab monotherapy against investigator's choice of R-GemOx or bendamustine-rituximab in relapsed/refractory DLBCL.

Dr. Johnson addresses whether using CD19-directed agents in the frontline compromises subsequent relapse options.

Dr. Graff discusses the challenging scenario of a positive interim PET scan mid-treatment.

Dr. Johnson confirms dose-adjusted R-EPOCH as his standard for the vast majority of double-hit patients outside clinical trials, noting POLARIX and frontMIND each included only approximately 6% to 8% double-hit patients, far too few for meaningful subgroup analysis.

Dr. Graff addresses whether the absence of overall survival benefit from either POLARIX or frontMIND should discourage adoption.

Dr. Lunning discusses decision-making when both Pola-R-CHP and Tafa-Len-R-CHOP are options.

Experts review new Phase 3 DLBCL data, Pola-R-CHP adoption, biomarker testing, and emerging molecular risk groups as bispecific antibodies reshape relapsed care.

Experts review new Phase 3 DLBCL data, Pola-R-CHP adoption, biomarker testing, and emerging molecular risk groups as bispecific antibodies reshape relapsed care.

Francine Foss, MD, and Matthew Lunning, DO, FACP, discuss other key data from ASH 2025 and ongoing research to watch in peripheral T-cell lymphoma.

Francine Foss, MD, and Matthew Lunning, DO, FACP, discuss findings for duvelisib plus chidamide and CHOP in newly diagnosed angioimmunoblastic T-cell lymphoma.

Francine Foss, MD, and Matthew Lunning, DO, FACP, look ahead to the phase 3 TERZO trial of duvelisib in nodal TFH peripheral T-cell lymphoma.

Francine Foss, MD, and Matthew Lunning, DO, FACP, highlight key findings from the PRIMO trial evaluating duvelisib in relapsed/refractory peripheral T-cell lymphoma.

Francine Foss, MD, and Matthew Lunning, DO, FACP, discuss varying treatment approaches for peripheral T-cell lymphoma in newly diagnosed vs relapsed disease.

Francine Foss, MD, and Matthew Lunning, DO, FACP, detail current treatment approaches for peripheral T-cell lymphoma.

Drs Lunning and Rutherford discuss findings from the ECHELON-1 trial of BV-AVD in the cohort of patients with Hodgkin lymphoma over 60 years of age.

Dr Lunning sits down with Alex Herrera, MD, to discuss the frontline management of Hodgkin lymphoma, including the SWOG 1826 trial.

Matthew Lunning, DO, FACP, discusses considerations for community oncologists who treat patients with relapsed/refractory follicular lymphoma.

A panel of experts discuss the future of R/R DLBCL treatment and review some recent data from the 2022 ASH meeting.

Experts discuss the potential use of CAR T-cell therapy in the front line setting as well as reviewing the use of tafasitamab from the FRONT-MIND and FIRST-MIND trials.

Insightful discussion among a panel of oncologists on how to best sequence therapies for patients with R/R DLBCL.

Experts review some of the safety outcomes from the ZUMA-7 trial as well as discussing the clinical implications of the ZUMA-7 trial into their practice.

An overview of the ZUMA-7 and the TRANSFORM trial as well as reviewing eligibility criteria for patients who might receive CAR-T therapy.

Panel of experts discuss where CAR T-cell therapy might fit into the treatment landscape for patients with R/R DLBCL.

Comprehensive insight into the L-MIND trial including a review of efficacy outcomes as well as discussing the implications of the data into clinical practice.

Experts discuss which factors are considered when choosing treatment options for patients with R/R DLBCL as well as reviewing the mechanism of tafasitamab.

Insightful discussion among experts into a brief overview of relapsed/refractory DLBCL (R/R DLBCL).

Expert oncologists provide a brief overview of front-line treatment options for patients diagnosed with double large b-cell lymphoma (DLBCL).